Prognostic Impact of Peripheral Blood T-Cell Subsets at the Time of Diagnosis on Survival in Patients with Diffuse Large B-Cell Lymphoma

被引:9
|
作者
Shin, Ho-Jin [1 ]
Kim, Do-Young [1 ]
Chung, JooSeop [1 ]
Shin, Kyung-Hwa [2 ]
Lee, Hyungi [3 ]
机构
[1] Pusan Natl Univ Hosp, Sch Med, Med Res Inst, Dept Internal Med,Div Hematol Oncol, Busan, South Korea
[2] Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Lab Med, Busan, South Korea
[3] Pusan Natl Univ Hosp, Clin Trial Ctr, Busan, South Korea
关键词
Diffuse large B-cell lymphoma; T-cell subsets; Peripheral blood; Survival; NATURAL-KILLER-CELLS; ABSOLUTE LYMPHOCYTE; COUNT; CHEMOTHERAPY; CHOP;
D O I
10.1159/000510912
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The effects of lymphocyte subtypes, including helper (Th), natural killer (NK), and regulatory (Treg) cells, and other T-cell subtypes on treatment outcomes in diffuse large B-cell lymphoma (DLBCL) patients are not clearly established. Methods: Among 151 consecutive patients diagnosed with DLBCL, we collected peripheral blood samples at diagnosis from 91 patients who received at least 1 cycle of R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab) chemotherapy and analyzed lymphocyte subsets by flow cytometry. Results: DLBCL patients had a higher proportion of CD4(+)CD25(+) Treg (p < 0.001) and lower absolute lymphocyte count than those of healthy controls. Lymphopenia at diagnosis was associated with advanced-stage disease (p = 0.001), a high-intermediate/high-risk International Prognostic Index (IPI) (p < 0.001), and older age (p = 0.060). High-intermediate/high-risk IPI, high proportion of CD3(+)CD4(+) Th cells, and extranodal site >= 2 correlated with unfavorable prognostic factors for survival. High proportion of Th cells was associated with fewer cytotoxic T cells and NK cells at the time of diagnosis. Conclusion: This study showed an association between circulating lymphocyte subsets including Th cells, Tregs, and NK cells and clinical outcomes in DLBCL; however, further confirmation is needed via prospective trials.
引用
收藏
页码:427 / 437
页数:11
相关论文
共 50 条
  • [21] Clinical characteristics and prognostic analysis of Chinese patients with diffuse large B-cell lymphoma
    Ke, Xiaoyan
    Wang, Jing
    Gao, Zifen
    Zhao, Lingzhi
    Li, Min
    Jing, Hongmei
    Wang, Jijun
    Zhao, Wei
    Gilbert, Heather
    Yang, Xiao-Feng
    BLOOD CELLS MOLECULES AND DISEASES, 2010, 44 (01) : 55 - 61
  • [22] Predictors of delay in diagnosis and treatment in diffuse large B-cell lymphoma and impact on survival
    Nikonova, Anna
    Guirguis, Hany R.
    Buckstein, Rena
    Cheung, Matthew C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (04) : 492 - 500
  • [23] Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma:: a multiparameter flow cytometry study
    Xu, Y
    Kroft, SH
    McKenna, RW
    Aquino, DB
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (04) : 945 - 949
  • [24] Refining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma
    Balague, O.
    Campo, E.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 918 - 920
  • [25] Prognostic factors for primary diffuse large B-cell lymphoma of the brain
    Zhou, Zhuoya
    Chen, Jing
    ASIAN JOURNAL OF SURGERY, 2023, 46 (10) : 4357 - 4362
  • [26] Prognostic Value of Platelet Count in Diffuse Large B-Cell Lymphoma
    Chen, Ling-Ping
    Lin, Shyh-Jer
    Yu, Ming-Sun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (01) : 32 - 37
  • [27] The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma
    Habbous, Steven
    Guo, Helen
    Beca, Jaclyn
    Dai, Wei Fang
    Isaranuwatchai, Wanrudee
    Cheung, Matthew
    Chan, Kelvin K. W.
    CANCER MEDICINE, 2020, 9 (19): : 7072 - 7082
  • [28] Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma
    Puig, Noemi
    Wang, Lisa
    Seshadri, Tara
    al-Farsi, Khalil
    Keating, Armand
    Crump, Michael
    Kuruvilla, John
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 507 - 513
  • [29] Insurance status is related to diffuse large B-cell lymphoma survival
    Han, Xuesong
    Jemal, Ahmedin
    Flowers, Christopher R.
    Sineshaw, Helmneh
    Nastoupil, Loretta J.
    Ward, Elizabeth
    CANCER, 2014, 120 (08) : 1220 - 1227
  • [30] Expression of SATB1 is a prognostic indicator for survival in diffuse large B-cell lymphoma patients
    Yi, H.
    Wei, Y.
    Chen, J-J
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (02) : 382 - 390